Obeso, JA, Olanow, CW, Nutt, JG. Levodopa motor complications in Parkinson’s disease. Trends in neurosciences 2000;23:S2–7.CrossRefGoogle ScholarPubMed

Olanow, CW. The scientific basis for the current treatment of Parkinson’s disease. Annual review of medicine 2004;55:41–60.CrossRefGoogle ScholarPubMed

Voon, V, Fernagut, PO, Wickens, J, et al. Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet neurology 2009;8:1140–1149.CrossRefGoogle ScholarPubMed

Nutt, JG, Chung, KA, Holford, NH. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 2010;74:1191–1197.CrossRefGoogle ScholarPubMed

Fahn, S, Jankovic, J, Hallett, M. Principles and practice of movement disorders, 2nd ed. Edinburgh; New York: Elsevier/Saunders, 2011.Google Scholar

Hauser, RA, Friedlander, J, Zesiewicz, TA, et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clinical neuropharmacology 2000;23:75–81.CrossRefGoogle ScholarPubMed

Fabbrini, G, Brotchie, JM, Grandas, F, Nomoto, M, Goetz, CG. Levodopa-induced dyskinesias. Movement disorders: official journal of the Movement Disorder Society 2007; 22:1379–1389;quiz 1523.CrossRefGoogle ScholarPubMed

Reimer, J, Grabowski, M, Lindvall, O, Hagell, P. Use and interpretation of on/off diaries in Parkinson’s disease. Journal of neurology, neurosurgery, and psychiatry 2004;75:396–400.CrossRefGoogle Scholar

Colosimo, C, Martinez-Martin, P, Fabbrini, G, et al. Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations. Movement disorders: official journal of the Movement Disorder Society 2010;25:1131–1142.CrossRefGoogle ScholarPubMed

Goetz, CG, Stebbins, GT, Chung, KA, et al. Which dyskinesia scale best detects treatment response? Movement disorders: official journal of the Movement Disorder Society 2013;28:341–346.CrossRefGoogle ScholarPubMed

Stacy, MA, Murphy, JM, Greeley, DR, et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism & related disorders 2008;14:205–212.CrossRefGoogle ScholarPubMed

Katzenschlager, R, Schrag, A, Evans, A, et al. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure. Neurology 2007;69:555–563.CrossRefGoogle ScholarPubMed

Jankovic, J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Movement disorders: official journal of the Movement Disorder Society 2005;20 Suppl 11:S11–16.CrossRefGoogle ScholarPubMed

Schrag, A, Ben-Shlomo, Y, Brown, R, Marsden, CD, Quinn, N. Young-onset Parkinson’s disease revisited–clinical features, natural history, and mortality. Movement disorders: official journal of the Movement Disorder Society 1998;13:885–894.CrossRefGoogle ScholarPubMed

Blanchet, PJ, Allard, P, Gregoire, L, Tardif, F, Bedard, PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1996;23:189–193.CrossRefGoogle ScholarPubMed

Kumar, N, Van Gerpen, JA, Bower, JH, Ahlskog, JE. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Movement disorders: official journal of the Movement Disorder Society 2005;20:342–344.CrossRefGoogle ScholarPubMed

Ku, S, Glass, GA. Age of Parkinson’s disease onset as a predictor for the development of dyskinesia. Movement disorders: official journal of the Movement Disorder Society 2010;25:1177–1182.CrossRefGoogle ScholarPubMed

Di Monte, DA, McCormack, A, Petzinger, G, Janson, AM, Quik, M, Langston, WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Movement disorders: official journal of the Movement Disorder Society 2000;15:459–466.3.0.CO;2-3>CrossRefGoogle ScholarPubMed

Vidailhet, M, Bonnet, AM, Marconi, R, Gouider-Khouja, N, Agid, Y. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Neurology 1994;44:1613–1616.CrossRefGoogle ScholarPubMed

Khan, NL, Graham, E, Critchley, P, et al. Parkin disease: a phenotypic study of a large case series. Brain: a journal of neurology 2003;126:1279–1292.CrossRefGoogle ScholarPubMed

Scherfler, C, Khan, NL, Pavese, N, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain: a journal of neurology 2004;127:1332–1342.CrossRefGoogle ScholarPubMed

Calon, F, Morissette, M, Rajput, AH, Hornykiewicz, O, Bedard, PJ, Di Paolo, T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Movement disorders: official journal of the Movement Disorder Society 2003;18:241–253.CrossRefGoogle ScholarPubMed

Togasaki, DM, Tan, L, Protell, P, Di Monte, DA, Quik, M, Langston, JW. Levodopa induces dyskinesias in normal squirrel monkeys. Annals of neurology 2001;50:254–257.CrossRefGoogle ScholarPubMed

de la Fuente-Fernandez, R, Schulzer, M, Mak, E, Calne, DB, Stoessl, AJ. Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model. Brain: a journal of neurology 2004;127:888–899.CrossRefGoogle ScholarPubMed

Linazasoro, G, Antonini, A, Maguire, RP, Leenders, KL. Pharmacological and PET studies in patients with Parkinson’s disease and a short duration-motor response: implications in the pathophysiology of motor complications. Journal of neural transmission 2004;111:497–509.CrossRefGoogle Scholar

Troiano, AR, de la Fuente-Fernandez, R, Sossi, V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009;72:1211–1216.CrossRefGoogle ScholarPubMed

Hong, JY, Oh, JS, Lee, I, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology 2014;82:1597–1604.CrossRefGoogle ScholarPubMed

Linazasoro, G, Van Blercom, N, Bergaretxe, A, Inaki, FM, Laborda, E, Ruiz Ortega, JA. Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study. Clinical neuropharmacology 2009;32:326–329.CrossRefGoogle ScholarPubMed

Schneider, JS, Gonczi, H, Decamp, E. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Brain research 2003;990:38–44.CrossRefGoogle ScholarPubMed

Ahlskog, JE, Muenter, MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement disorders: official journal of the Movement Disorder Society 2001;16:448–458.CrossRefGoogle ScholarPubMed

Fahn, S, Oakes, D, Shoulson, I, et al. Levodopa and the progression of Parkinson’s disease. The New England journal of medicine 2004;351:2498–2508.Google Scholar

Khan, NL, Valente, EM, Bentivoglio, AR, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Annals of neurology 2002;52:849–853.CrossRefGoogle ScholarPubMed

Dekker, M, Bonifati, V, van Swieten, J, et al. Clinical features and neuroimaging of PARK7-linked parkinsonism. Movement disorders: official journal of the Movement Disorder Society 2003;18:751–757.CrossRefGoogle ScholarPubMed

Rascol, O, Brooks, DJ, Korczyn, AD, De Deyn, PP, Clarke, CE, Lang, AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. The New England journal of medicine 2000;342:1484–1491.CrossRefGoogle ScholarPubMed

Hauser, RA, Rascol, O, Korczyn, AD, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Movement disorders: official journal of the Movement Disorder Society 2007;22:2409–2417.CrossRefGoogle ScholarPubMed

Lopez, IC, Ruiz, PJ, Del Pozo, SV, Bernardos, VS. Motor complications in Parkinson’s disease: ten year follow-up study. Movement disorders: official journal of the Movement Disorder Society 2010;25:2735–2739.CrossRefGoogle ScholarPubMed

Zappia, M, Annesi, G, Nicoletti, G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Archives of neurology 2005;62:601–605.CrossRefGoogle ScholarPubMed

Wang, J, Liu, ZL, Chen, B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001;56:1757–1759.CrossRefGoogle ScholarPubMed

Lee, JY, Cho, J, Lee, EK, Park, SS, Jeon, BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2011;26:73–79.CrossRefGoogle ScholarPubMed

Foltynie, T, Cheeran, B, Williams-Gray, CH, et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease. Journal of neurology, neurosurgery, and psychiatry 2009;80:141–144.CrossRefGoogle ScholarPubMed

Obeso, JA, Grandas, F, Herrero, MT, Horowski, R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson’s disease. The European journal of neuroscience 1994;6:889–897.CrossRefGoogle Scholar

Calabresi, P, Di Filippo, M, Ghiglieri, V, Picconi, B. Molecular mechanisms underlying levodopa-induced dyskinesia. Movement disorders: official journal of the Movement Disorder Society 2008;23 Suppl 3:S570–579.CrossRefGoogle ScholarPubMed

Grace, AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1–24.CrossRefGoogle ScholarPubMed

Venton, BJ, Zhang, H, Garris, PA, Phillips, PE, Sulzer, D, Wightman, RM. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. Journal of neurochemistry 2003;87:1284–1295.CrossRefGoogle ScholarPubMed

Zigmond, MJ, Abercrombie, ED, Berger, TW, Grace, AA, Stricker, EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends in neurosciences 1990;13:290–296.CrossRefGoogle ScholarPubMed

Lewitt, PA, Mouradian, MM. Predicting the development of levodopa-induced dyskinesias: A presynaptic mechanism? Neurology 2014;82:1574–1575.CrossRefGoogle ScholarPubMed

Bezard, E, Brotchie, JM, Gross, CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature reviews Neuroscience 2001;2:577–588.CrossRefGoogle ScholarPubMed

Jenner, P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature reviews Neuroscience 2008;9:665–677.CrossRefGoogle ScholarPubMed

Berthet, A, Bezard, E. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism & related disorders 2009;15 Suppl 4:S8–12.CrossRefGoogle ScholarPubMed

Missale, C, Nash, SR, Robinson, SW, Jaber, M, Caron, MG. Dopamine receptors: from structure to function. Physiological reviews 1998;78:189–225.CrossRefGoogle ScholarPubMed

Le Moine, C, Bloch, B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. The Journal of comparative neurology 1995;355:418–426.CrossRefGoogle ScholarPubMed

Landwehrmeyer, B, Mengod, G, Palacios, JM. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. The European journal of neuroscience 1993;5:145–153.CrossRefGoogle Scholar

Bezard, E, Ferry, S, Mach, U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature medicine 2003;9:762–767.CrossRefGoogle ScholarPubMed

Gerfen, CR, Engber, TM, Mahan, LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429–1432.CrossRefGoogle ScholarPubMed

Alexander, GE, Crutcher, MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends in neurosciences 1990;13:266–271.CrossRefGoogle ScholarPubMed

Le, W, Sayana, P, Jankovic, J. Animal models of Parkinson’s disease: a gateway to therapeutics? Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 2014;11:92–110.CrossRefGoogle ScholarPubMed

Di Chiara, G, Morelli, M, Barone, P, Pontieri, F. Priming as a model of behavioural sensitization. Developmental pharmacology and therapeutics 1992;18:223–227.CrossRefGoogle Scholar

Morelli, M, Fenu, S, Garau, L, Di Chiara, G. Time and dose dependence of the ‘priming’ of the expression of dopamine receptor supersensitivity. European journal of pharmacology 1989;162:329–335.CrossRefGoogle ScholarPubMed

Cenci, MA, Lee, CS, Bjorklund, A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. The European journal of neuroscience 1998;10:2694–2706.Google ScholarPubMed

Lundblad, M, Andersson, M, Winkler, C, Kirik, D, Wierup, N, Cenci, MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. The European journal of neuroscience 2002;15:120–132.CrossRefGoogle Scholar

Picconi, B, Centonze, D, Rossi, S, Bernardi, G, Calabresi, P. Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain: a journal of neurology 2004;127:1661–1669.CrossRefGoogle ScholarPubMed

Gasparini, F, Di Paolo, T, Gomez-Mancilla, B. Metabotropic glutamate receptors for Parkinson’s disease therapy. Parkinson’s disease 2013;2013:196028.Google ScholarPubMed

van Zundert, B, Yoshii, A, Constantine-Paton, M. Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal. Trends in neurosciences 2004;27:428–437.CrossRefGoogle ScholarPubMed

Hurley, MJ, Jackson, MJ, Smith, LA, Rose, S, Jenner, P. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. The European journal of neuroscience 2005;21:3240–3250.CrossRefGoogle ScholarPubMed

Bibbiani, F, Oh, JD, Kielaite, A, Collins, MA, Smith, C, Chase, TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Experimental neurology 2005;196:422–429.CrossRefGoogle ScholarPubMed

Del Dotto, P, Pavese, N, Gambaccini, G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement disorders: official journal of the Movement Disorder Society 2001;16:515–520.CrossRefGoogle ScholarPubMed

Gardoni, F, Picconi, B, Ghiglieri, V, et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. The Journal of neuroscience: the official journal of the Society for Neuroscience 2006;26:2914–2922.CrossRefGoogle ScholarPubMed

Missale, C, Fiorentini, C, Busi, C, Collo, G, Spano, PF. The NMDA/D1 receptor complex as a new target in drug development. Current topics in medicinal chemistry 2006;6:801–808.CrossRefGoogle ScholarPubMed

Hallett, PJ, Spoelgen, R, Hyman, BT, Standaert, DG, Dunah, AW. Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. The Journal of neuroscience: the official journal of the Society for Neuroscience 2006;26:4690–4700.CrossRefGoogle ScholarPubMed

Schwarzschild, MA, Agnati, L, Fuxe, K, Chen, JF, Morelli, M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends in neurosciences 2006;29:647–654.CrossRefGoogle ScholarPubMed

Xiao, D, Bastia, E, Xu, YH, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 2006;26:13548–13555.CrossRefGoogle ScholarPubMed

Calon, F, Dridi, M, Hornykiewicz, O, Bedard, PJ, Rajput, AH, Di Paolo, T. Increased adenosine A2A receptors in the brain of Parkinson’s disease patients with dyskinesias. Brain: a journal of neurology 2004;127:1075–1084.CrossRefGoogle ScholarPubMed

Carta, AR, Pinna, A, Cauli, O, Morelli, M. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse 2002;44:166–174.CrossRefGoogle ScholarPubMed

Linazasoro, G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends in pharmacological sciences 2005;26:391–397.CrossRefGoogle ScholarPubMed

Robertson, HA, Peterson, MR, Murphy, K, Robertson, GS. D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour. Brain research 1989;503:346–349.CrossRefGoogle ScholarPubMed

Dragunow, M, Robertson, GS, Faull, RL, Robertson, HA, Jansen, K. D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 1990;37:287–294.CrossRefGoogle ScholarPubMed

Graybiel, AM, Moratalla, R, Robertson, HA. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proceedings of the National Academy of Sciences of the United States of America 1990;87:6912–6916.CrossRefGoogle ScholarPubMed

Calon, F, Hadj Tahar, A, Blanchet, PJ, et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends in neurosciences 2000;23:S92–100.CrossRefGoogle ScholarPubMed

Dunnett, S. L-DOPA, dyskinesia and striatal plasticity. Nature neuroscience 2003;6:437–438.CrossRefGoogle ScholarPubMed

Picconi, B, Centonze, D, Hakansson, K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature neuroscience 2003;6:501–506.CrossRefGoogle ScholarPubMed

Greengard, P, Allen, PB, Nairn, AC. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999;23:435–447.CrossRefGoogle ScholarPubMed

Walaas, SI, Hemmings, HC, Greengard, P, Nairn, AC. Beyond the dopamine receptor: regulation and roles of serine/threonine protein phosphatases. Frontiers in neuroanatomy 2011;5:50.CrossRefGoogle ScholarPubMed

Morelli, M, Cozzolino, A, Pinna, A, Fenu, S, Carta, A, Di Chiara, G. L-dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors. Brain research 1993;623:334–336.CrossRefGoogle ScholarPubMed

Steiner, H, Gerfen, CR. Dynorphin opioid inhibition of cocaine-induced, D1 dopamine receptor-mediated immediate-early gene expression in the striatum. The Journal of comparative neurology 1995;353:200–212.CrossRefGoogle ScholarPubMed

Gerfen, CR, Keefe, KA, Gauda, EB. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. The Journal of neuroscience: the official journal of the Society for Neuroscience 1995;15:8167–8176.CrossRefGoogle ScholarPubMed

Robertson, GS, Vincent, SR, Fibiger, HC. Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos. Brain research 1990;523:288–290.CrossRefGoogle ScholarPubMed

Keefe, KA, Gerfen, CR. D1 dopamine receptor-mediated induction of zif268 and c-fos in the dopamine-depleted striatum: differential regulation and independence from NMDA receptors. The Journal of comparative neurology 1996;367:165–176.3.0.CO;2-3>CrossRefGoogle ScholarPubMed

Konradi, C, Leveque, JC, Hyman, SE. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. The Journal of neuroscience: the official journal of the Society for Neuroscience 1996;16:4231–4239.CrossRefGoogle ScholarPubMed

Berke, JD, Paletzki, RF, Aronson, GJ, Hyman, SE, Gerfen, CR. A complex program of striatal gene expression induced by dopaminergic stimulation. The Journal of neuroscience: the official journal of the Society for Neuroscience 1998;18:5301–5310.CrossRefGoogle ScholarPubMed

Juncos, JL, Engber, TM, Raisman, R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Annals of neurology 1989;25:473–478.CrossRefGoogle ScholarPubMed

Konradi, C, Heckers, S. Haloperidol-induced Fos expression in striatum is dependent upon transcription factor cyclic AMP response element binding protein. Neuroscience 1995;65:1051–1061.CrossRefGoogle ScholarPubMed

Huang, KX, Walters, JR. Dopaminergic regulation of AP-1 transcription factor DNA binding activity in rat striatum. Neuroscience 1996;75:757–775.CrossRefGoogle ScholarPubMed

Aubert, I, Guigoni, C, Hakansson, K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of neurology 2005;57:17–26.CrossRefGoogle ScholarPubMed

Guigoni, C, Doudnikoff, E, Li, Q, Bloch, B, Bezard, E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiology of disease 2007;26:452–463.CrossRefGoogle ScholarPubMed

Berthet, A, Porras, G, Doudnikoff, E, et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. The Journal of neuroscience: the official journal of the Society for Neuroscience 2009;29:4829–4835.CrossRefGoogle ScholarPubMed

Bezard, E, Gross, CE, Qin, L, Gurevich, VV, Benovic, JL, Gurevich, EV. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiology of disease 2005;18:323–335.CrossRefGoogle ScholarPubMed

Ahmed, MR, Bychkov, E, Gurevich, VV, Benovic, JL, Gurevich, EV. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. Journal of neurochemistry 2008;104:1622–1636.CrossRefGoogle Scholar

Hallett, PJ, Dunah, AW, Ravenscroft, P, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Neuropharmacology 2005;48:503–516.CrossRefGoogle ScholarPubMed

Silverdale, MA, Kobylecki, C, Hallett, PJ, et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 2010;64:177–180.CrossRefGoogle ScholarPubMed

Gross, CE, Ravenscroft, P, Dovero, S, Jaber, M, Bioulac, B, Bezard, E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. Journal of neurochemistry 2003;84:1246–1255.CrossRefGoogle ScholarPubMed

Bordet, R, Ridray, S, Carboni, S, Diaz, J, Sokoloff, P, Schwartz, JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proceedings of the National Academy of Sciences of the United States of America 1997;94:3363–3367.CrossRefGoogle ScholarPubMed

Fiorentini, C, Busi, C, Gorruso, E, Gotti, C, Spano, P, Missale, C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Molecular pharmacology 2008;74:59–69.CrossRefGoogle ScholarPubMed

Marcellino, D, Ferre, S, Casado, V, et al. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. The Journal of biological chemistry 2008;283:26016–26025.CrossRefGoogle ScholarPubMed

Brambilla, R. Targeting Ras/ERK signaling in the striatum: will it help? Molecular psychiatry 2003;8:366–368.CrossRefGoogle ScholarPubMed

Valjent, E, Pascoli, V, Svenningsson, P, et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proceedings of the National Academy of Sciences of the United States of America 2005;102:491–496.CrossRefGoogle ScholarPubMed

Westin, JE, Vercammen, L, Strome, EM, Konradi, C, Cenci, MA. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biological psychiatry 2007;62:800–810.CrossRefGoogle Scholar

Morelli, M, Di Chiara, G. Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning. European journal of pharmacology 1987;141:101–107.CrossRefGoogle ScholarPubMed

Calabresi, P, Gubellini, P, Centonze, D, et al. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. The Journal of neuroscience: the official journal of the Society for Neuroscience 2000;20:8443–8451.CrossRefGoogle ScholarPubMed

Calabresi, P, Picconi, B, Parnetti, L, Di Filippo, M. A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine-acetylcholine synaptic balance. Lancet neurology 2006;5:974–983.CrossRefGoogle ScholarPubMed

Calabresi, P, Picconi, B, Tozzi, A, Di Filippo, M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in neurosciences 2007;30:211–219.CrossRefGoogle ScholarPubMed

Centonze, D, Grande, C, Saulle, E, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. The Journal of neuroscience: the official journal of the Society for Neuroscience 2003;23:8506–8512.CrossRefGoogle ScholarPubMed

Morgante, F, Espay, AJ, Gunraj, C, Lang, AE, Chen, R. Motor cortex plasticity in Parkinson’s disease and levodopa-induced dyskinesias. Brain: a journal of neurology 2006;129:1059–1069.CrossRefGoogle ScholarPubMed

Grondin, R, Doan, VD, Gregoire, L, Bedard, PJ. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 1999;52:771–776.CrossRefGoogle ScholarPubMed

Meissner, W, Ravenscroft, P, Reese, R, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiology of disease 2006;22:586–598.CrossRefGoogle ScholarPubMed

Carta, M, Lindgren, HS, Lundblad, M, Stancampiano, R, Fadda, F, Cenci, MA. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. Journal of neurochemistry 2006;96:1718–1727.CrossRefGoogle ScholarPubMed

de la Fuente-Fernandez, R, Sossi, V, Huang, Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain: a journal of neurology 2004;127:2747–2754.CrossRefGoogle ScholarPubMed

Cenci, MA, Lundblad, M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. Journal of neurochemistry 2006;99:381–392.CrossRefGoogle ScholarPubMed

Poewe, W, Mahlknecht, P, Jankovic, J. Emerging therapies for Parkinson’s disease. Current opinion in neurology 2012;25:448–459.CrossRefGoogle ScholarPubMed

Napolitano, M, Picconi, B, Centonze, D, Bernardi, G, Calabresi, P, Gulino, A. L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases. Neuroscience letters 2006;398:211–214.CrossRefGoogle ScholarPubMed

Smith, Y, Raju, D, Nanda, B, Pare, JF, Galvan, A, Wichmann, T. The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states. Brain research bulletin 2009;78:60–68.CrossRefGoogle ScholarPubMed

Blandini, F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson’s disease. Functional neurology 2010;25:65–71.Google ScholarPubMed

Bargiotas, P, Konitsiotis, S. Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments. Neuropsychiatric disease and treatment 2013;9:1605–1617.Google ScholarPubMed

Luginger, E, Wenning, GK, Bosch, S, Poewe, W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2000;15:873–878.3.0.CO;2-I>CrossRefGoogle ScholarPubMed

Verhagen Metman, L, Del Dotto, P, van den Munckhof, P, Fang, J, Mouradian, MM, Chase, TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 1998;50:1323–1326.CrossRefGoogle ScholarPubMed

da Silva-Junior, FP, Braga-Neto, P, Sueli Monte, F, de Bruin, VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism & related disorders 2005;11:449–452.CrossRefGoogle ScholarPubMed

Thomas, A, Iacono, D, Luciano, AL, Armellino, K, Di Iorio, A, Onofrj, M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. Journal of neurology, neurosurgery, and psychiatry 2004;75:141–143.Google ScholarPubMed

Metman, LV, Del Dotto, P, LePoole, K, Konitsiotis, S, Fang, J, Chase, TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Archives of neurology 1999;56:1383–1386.CrossRefGoogle ScholarPubMed

Wolf, E, Seppi, K, Katzenschlager, R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2010;25:1357–1363.CrossRefGoogle ScholarPubMed

Jahangirvand, AR, A. Early use of amantadine to prevent or delay onset of levodopa-induced dyskinesia in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2013;28:207.Google Scholar

F CJ, Ory-Magne, Azulay, JP, Bonnet, AM, Brefel-Courbon, C, Damier, P, Dellapina, E, Destée, A, Durif, F, Galitzky, M, Lebouvier, T, Meissner, W, Thalamas, C, Tison, F, Salis, A, Sommet, A, Viallet, F, Vidailhet, M, Rascol, O; NS-Park CIC Network. Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology 2014;82:300–307.Google Scholar

Pahwa, RT, Hauser, C., Sethi, R., Isaacson, K., Truong, D., Struck, D., Stempien, L., Went, M., G. Randomized trial of extended release amantadine in Parkinson’s disease patients with levodopa-induced dyskinesia (EASED study). Movement disorders: official journal of the Movement Disorder Society 2013;28:158.Google Scholar

Parkinson Study, G. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Archives of neurology 2001;58:1660–1668.Google Scholar

Bara-Jimenez, W, Dimitrova, TD, Sherzai, A, Aksu, M, Chase, TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Movement disorders: official journal of the Movement Disorder Society 2006;21:1380–1383.CrossRefGoogle ScholarPubMed

Verhagen Metman, L, Del Dotto, P, Natte, R, van den Munckhof, P, Chase, TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson’s disease. Neurology 1998;51:203–206.CrossRefGoogle ScholarPubMed

Pharmaceuticals, A. Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson’s Disease Patients (LID in PD) [online]. Available at: http://clinicaltrials.gov/show/NCT01767129. Accessed April 30, 2014.Google Scholar

Merello, M, Nouzeilles, MI, Cammarota, A, Leiguarda, R. Effect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized study. Clinical neuropharmacology 1999;22:273–276.Google ScholarPubMed

Moreau, C, Delval, A, Tiffreau, V, et al. Memantine for axial signs in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot study. Journal of neurology, neurosurgery, and psychiatry 2013;84:552–555.CrossRefGoogle ScholarPubMed

Vidal, EI, Fukushima, FB, Valle, AP, Villas Boas, PJ. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson’s disease dementia. Journal of the American Geriatrics Society 2013;61:170–172.CrossRefGoogle ScholarPubMed

Nash, JE, Ravenscroft, P, McGuire, S, Crossman, AR, Menniti, FS, Brotchie, JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson’s disease. Experimental neurology 2004;188:471–479.CrossRefGoogle ScholarPubMed

Nutt, JG, Gunzler, SA, Kirchhoff, T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Movement disorders: official journal of the Movement Disorder Society 2008;23:1860–1866.CrossRefGoogle ScholarPubMed

Ltd. NP. A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson’s Disease With Levodopa Induced Dyskinesia [online]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00607451?term=NCT00607451%26rank=1. Accessed April 30, 2014.Google Scholar

Picconi, B, Calabresi, P. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson’s disease? Movement disorders: official journal of the Movement Disorder Society 2014;29:715–719.CrossRefGoogle ScholarPubMed

Dekundy, A, Pietraszek, M, Schaefer, D, Cenci, MA, Danysz, W. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson’s disease. Brain research bulletin 2006;69:318–326.CrossRefGoogle Scholar

Johnston, TH, Fox, SH, McIldowie, MJ, Piggott, MJ, Brotchie, JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. The Journal of pharmacology and experimental therapeutics 2010;333:865–873.CrossRefGoogle Scholar

Levandis, G, Bazzini, E, Armentero, MT, Nappi, G, Blandini, F. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neurobiology of disease 2008;29:161–168.CrossRefGoogle ScholarPubMed

Gregoire, L, Morin, N, Ouattara, B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism & related disorders 2011;17:270–276.CrossRefGoogle ScholarPubMed

Stocchi, F, Rascol, O, Destee, A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Movement disorders: official journal of the Movement Disorder Society 2013;28:1838–1846.CrossRefGoogle ScholarPubMed

Pharmaceuticals, N. An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias [online]. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01173731?term=NCT01173731%26rank=1. Accessed April 30, 2014.Google Scholar

Tison, FD, Corvol, J, Eggert, K, Trenkwalder, C, Lew, M, Isaacson, S, Keywood, C, Rascol, O. Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Neurology 2013;80:004.CrossRefGoogle Scholar

Konitsiotis, S, Blanchet, PJ, Verhagen, L, Lamers, E, Chase, TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000;54:1589–1595.CrossRefGoogle ScholarPubMed

Eggert, K, Squillacote, D, Barone, P, et al. Safety and efficacy of perampanel in advanced Parkinson’s disease: a randomized, placebo-controlled study. Movement disorders: official journal of the Movement Disorder Society 2010;25:896–905.CrossRefGoogle ScholarPubMed

Lees, A, Fahn, S, Eggert, KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2012;27:284–288.CrossRefGoogle ScholarPubMed

Rascol, O, Barone, P, Behari, M, et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clinical neuropharmacology 2012;35:15–20.CrossRefGoogle ScholarPubMed

Savola, JM, Hill, M, Engstrom, M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2003;18:872–883.CrossRefGoogle ScholarPubMed

Lewitt, PA, Hauser, RA, Lu, M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012;79:163–169.CrossRefGoogle ScholarPubMed

Grondin, R, Hadj Tahar, A, Doan, VD, Ladure, P, Bedard, PJ. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedeberg’s archives of pharmacology 2000;361:181–186.CrossRefGoogle ScholarPubMed

Rascol, O, Arnulf, I, Peyro-Saint Paul, H, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2001;16:708–713.CrossRefGoogle ScholarPubMed

Manson, AJ, Iakovidou, E, Lees, AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2000;15:336–337.3.0.CO;2-R>CrossRefGoogle ScholarPubMed

Buck, K, Voehringer, P, Ferger, B. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Journal of neurochemistry 2010;112:444–452.CrossRefGoogle Scholar

Hodgson, RA, Bedard, PJ, Varty, GB, et al. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Experimental neurology 2010;225:384–390.CrossRefGoogle ScholarPubMed

Hauser, RA, Cantillon, M, Pourcher, E, et al. Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet neurology 2011;10:221–229.CrossRefGoogle ScholarPubMed

Factor, SA, Wolski, K, Togasaki, DM, et al. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society 2013;28:817–820.CrossRefGoogle ScholarPubMed

Jones, IW, Bolam, JP, Wonnacott, S. Presynaptic localisation of the nicotinic acetylcholine receptor beta2 subunit immunoreactivity in rat nigrostriatal dopaminergic neurones. The Journal of comparative neurology 2001;439:235–247.CrossRefGoogle ScholarPubMed

Durif, F, Debilly, B, Galitzky, M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004;62:381–388.CrossRefGoogle ScholarPubMed

Pierelli, F, Adipietro, A, Soldati, G, Fattapposta, F, Pozzessere, G, Scoppetta, C. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta neurologica Scandinavica 1998;97:295–299.CrossRefGoogle ScholarPubMed

Bennett, JP Jr., Landow, ER, Dietrich, S, Schuh, LA. Suppression of dyskinesias in advanced Parkinson’s disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Movement disorders: official journal of the Movement Disorder Society 1994;9:409–414.CrossRefGoogle ScholarPubMed

Meco, G, Stirpe, P, Edito, F, et al. Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. Journal of neural transmission 2009;116:881–884.CrossRefGoogle ScholarPubMed

Rascol, O, Bronzova, J, Hauser, RA, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism & related disorders 2012;18:370–376.CrossRefGoogle ScholarPubMed

Hauser, RA, Bronzova, J, Sampaio, C, et al. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson’s disease. European neurology 2009;62:40–48.CrossRefGoogle Scholar

Waters, CH, Sethi, KD, Hauser, RA, Molho, E, Bertoni, JM, Zydis Selegiline Study G. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Movement disorders: official journal of the Movement Disorder Society 2004;19:426–432.CrossRefGoogle Scholar

Rascol, O, Brooks, DJ, Melamed, E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947–954.CrossRefGoogle ScholarPubMed

Stocchi, F, Borgohain, R, Onofrj, M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Movement disorders: official journal of the Movement Disorder Society 2012;27:106–112.CrossRefGoogle ScholarPubMed

Carroll, CB, Bain, PG, Teare, L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63:1245–1250.CrossRefGoogle ScholarPubMed

Sugiyama, K, Yokoyama, T, Namba, H. [Neurosurgical treatment for dopamine-induced dyskinesias in Parkinson’s disease patients]. Nihon rinsho Japanese journal of clinical medicine 2000;58:2115–2119.Google ScholarPubMed

Munhoz, RP, Cerasa, A, Okun, MS. Surgical treatment of dyskinesia in Parkinson’s disease. Frontiers in neurology 2014;5:65.CrossRefGoogle ScholarPubMed

Deep-Brain Stimulation for Parkinson’s Disease Study G. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. The New England journal of medicine 2001;345:956–963.CrossRefGoogle Scholar

Rodriguez-Oroz, MC, Obeso, JA, Lang, AE, et al. Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain: a journal of neurology 2005;128:2240–2249.CrossRefGoogle ScholarPubMed

Volkmann, J, Allert, N, Voges, J, Sturm, V, Schnitzler, A, Freund, HJ. Long-term results of bilateral pallidal stimulation in Parkinson’s disease. Annals of neurology 2004;55:871–875.CrossRefGoogle ScholarPubMed

Krack, P, Batir, A, Van Blercom, N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. The New England journal of medicine 2003;349:1925–1934.CrossRefGoogle Scholar

Schupbach, WM, Chastan, N, Welter, ML, et al. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. Journal of neurology, neurosurgery, and psychiatry 2005;76:1640–1644.CrossRefGoogle ScholarPubMed

Kleiner-Fisman, G, Herzog, J, Fisman, DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Movement disorders: official journal of the Movement Disorder Society 2006;21 Suppl 14:S290–304.CrossRefGoogle ScholarPubMed

Odekerken, VJ, van Laar, T, Staal, MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet neurology 2013;12:37–44.CrossRefGoogle ScholarPubMed